Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of
Journal
Advances in radiation oncology
ISSN: 2452-1094
Titre abrégé: Adv Radiat Oncol
Pays: United States
ID NLM: 101677247
Informations de publication
Date de publication:
Historique:
received:
09
06
2020
revised:
02
08
2020
accepted:
14
08
2020
entrez:
1
2
2021
pubmed:
2
2
2021
medline:
2
2
2021
Statut:
epublish
Résumé
Our purpose was to investigate the effect of the addition of prostate-specific membrane antigen (PSMA)-targeted positron emission tomography/computed tomography (PET/CT) in patients with recurrent prostate cancer post-primary radiation therapy. A prospective, multi-institutional clinical trial evaluated 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid ( Most patients (59%) had a major change in actual management compared with pre-PET/CT proposed management. The rate of major change was underestimated by immediately post-PET/CT surveys (32%). Eighteen patients with PSMA avidity in the prostate gland suspicious for malignancy had a prostate biopsy. Sensitivity, specificity, and positive predictive values of PSMA uptake in the prostate were 86%, 67%, and 92%, respectively. Thirty percent of patients had directed salvage therapy and 41% underwent systemic therapy. Eleven out of 79 patients (14%) had high-dose-rate brachytherapy alone for local recurrence, and 91% were free of recurrence at a median follow-up of 20 months. Most patients had a major change in actual management compared with pre-PSMA-targeted PET/CT planned management, and this was underestimated by post-PET/CT questionnaires.
Identifiants
pubmed: 33521396
doi: 10.1016/j.adro.2020.08.010
pii: S2452-1094(20)30221-9
pmc: PMC7820022
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100553Informations de copyright
© 2020 The Author(s).
Références
Int J Radiat Oncol Biol Phys. 2020 Mar 1;106(3):546-555
pubmed: 31730876
Eur Urol. 2020 Apr;77(4):403-417
pubmed: 30773328
Cancers (Basel). 2019 May 23;11(5):
pubmed: 31126071
Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74
pubmed: 16798415
Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1047-55
pubmed: 15519774
Cancer Radiother. 2019 Oct;23(6-7):541-558
pubmed: 31421999
Adv Radiat Oncol. 2020 May 12;5(5):965-977
pubmed: 33083660
J Nucl Med. 2018 Jan;59(1):82-88
pubmed: 28646014
Eur Urol. 2018 Aug;74(2):179-190
pubmed: 29678358
J Nucl Med. 2018 Mar;59(3):434-441
pubmed: 29242398
J Nucl Med. 2017 Jun;58(6):947-952
pubmed: 27908968
Int J Radiat Oncol Biol Phys. 2020 May 1;107(1):126-135
pubmed: 32006609
EJNMMI Res. 2016 Dec;6(1):78
pubmed: 27785766
J Nucl Med. 2019 Nov;60(11):1587-1593
pubmed: 30979820
Eur Urol Oncol. 2020 May 22;:
pubmed: 32451312
JAMA Oncol. 2019 Jun 1;5(6):856-863
pubmed: 30920593
J Nucl Med. 2020 Aug;61(8):1153-1160
pubmed: 31924715